Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
Topline data were announced from a phase 3 trial evaluating ceralasertib plus Imfinzi in patients with locally advanced or metastatic NSCLC.
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...
Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...
British pharma AstraZeneca (LSE: AZN) said a Phase III study of ceralasertib combined with Imfinzi (durvalumab) failed to ...
AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...
AstraZeneca’s LATIFY phase III trial of ceralasertib plus Imfinzi in previously treated advanced NSCLC fails to meet primary endpoint: Cambridge, UK Tuesday, December 23, 2025, ...
AstraZeneca reports a Phase 3 lung cancer miss, FDA breakthrough status for Enhertu, and a $2 billion KRAS drug deal with ...
AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...
Zacks Investment Research on MSN
AZN, Daiichi's Enhertu gets breakthrough tag for expanded cancer use
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy ...
Investing.com -- AstraZeneca PLC (ST:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback